Akshay S. Desai

Jan 24, 2024 | jamanetwork.com | Orly Vardeny |Outcomes Research |Akshay S. Desai |Pardeep S. Jhund

Key PointsQuestion  What is the mode of death and the association of dapagliflozin with cause-specific death in patients with heart failure with improved ejection fraction (HFimpEF)? Findings  In this post hoc analysis of the DELIVER trial including 6263 participants, 1151 participants had HFimpEF.

Jan 2, 2024 | jacc.org | David A. Morrow |Eric Velazquez |Akshay S. Desai |Adam D. DeVore

References1. "Angiotensin-neprilysin inhibition versus enalapril in heart failure". N Engl J Med . 2014;371:993-1004. 2. "Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction". N Engl J Med . 2019;381:1609-1620. 3. "Rationale, design and baseline characteristics of the PARAGLIDE-HF trial: sacubitril/valsartan vs valsartan in HFmrEF and HFpEF with a worsening heart failure event". J Card Fail . 2023;29:922-930. 4.

Oct 9, 2023 | onlinelibrary.wiley.com | Jawad H. Butt |Kirsty McDowell |Toru Kondo |Akshay S. Desai

Introduction Red cell distribution width (RDW) is a measure of the heterogeneity in the size of circulating red cells, and it is routinely assessed as part of a complete blood cell count, but not always reported.1, 2 RDW is calculated by dividing the standard deviation of the red blood cell volume by the mean corpuscular volume multiplied by 100.1, 2 Higher RDW values reflect greater heterogeneity in red blood cell size (i.e. anisocytosis), and, together with other measures, it has...

Aug 2, 2023 | jacc.org | Safia Chatur |Muthiah Vaduganathan |Brian Claggett |Akshay S. Desai

STRUCTURED ABSTRACTBackgroundSGLT-2 inhibitors are guideline-recommended in the management of heart failure(HF). While these therapies can be initiated even in patients with comorbid CKD, some patients may face deterioration in kidney function over time. ObjectivesTo examine the safety and efficacy of continuing SGLT-2 inhibitors in HF when eGFR falls below thresholds for initiation.

Jun 27, 2023 | ahajournals.org | Toru Kondo |Pooja Dewan |Inder Anand |Akshay S. Desai

Originally publishedhttps://doi.org/10.1161/CIRCULATIONAHA.122.063642Circulation. 2023;0AbstractBACKGROUND:Recent guidelines proposed a classification for heart failure (HF) on the basis of left ventricular ejection fraction (LVEF), although it remains unclear whether the divisions chosen were biologically rational. Using patients spanning the full range of LVEF, we examined whether there was evidence of LVEF thresholds in patient characteristics or inflection points in clinical outcomes.